Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, “Off-the-Shelf”, Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
First allogeneic, off-the-shelf anti-CD38 DAR-T cell therapy cleared for Phase 1 clinical trial in Relapsed or Refractory Multiple Myeloma.CD38 DAR-T...